Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the voting results of its annual and special meeting of shareholders held on September 22, 2026. According to the company, 46,452,598 common shares were represented at the meeting, accounting for 63.58% of outstanding shares as of the record date. Shareholders approved several key proposals, including the appointment of Zeifmans LLP as auditor, setting the board size at eight directors, and electing Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall, and Eric So as directors. Additionally, shareholders approved changing the company's legal name from Cybin Inc. to Helus Pharma Inc., effective October 1. This legal name change follows the adoption of the Helus Pharma business name on January 5 and reflects the company's anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company.
The name change is more than a rebranding exercise; it underscores Helus Pharma's strategic pivot toward commercialization. The company, founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Its NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. It is also developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The meeting results and name change could have significant implications for investors and the pharmaceutical industry. The transition to a commercial-ready company may attract new investment and partnerships, potentially accelerating the development and commercialization of its NSA therapies. For patients with treatment-resistant depression and anxiety, the advancement of HLP003 and HLP004 represents hope for more effective treatments. The appointment of a diverse board with expertise in healthcare, finance, and corporate governance could guide the company through this critical phase.
The announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. The full press release can be viewed at https://nnw.fm/H4DVg. For terms of use and disclaimers, see https://www.NetworkNewsWire.com/Disclaimer.
